J.D. Spicer
McGill University Health Centre · 13 works · 266 citations · h-index 6
Top works
- LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
- LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC
- LBA57 Neoadjuvant nivolumab (N) + chemotherapy (C) in the phase III CheckMate 816 study: 3-y results by tumor PD-L1 expression
- OA01.03 Association of Pathologic Regression with EFS in the KEYNOTE-671 Study of Perioperative Pembrolizumab for Early-Stage NSCLC
- 1261O Neoadjuvant nivolumab (N) + ipilimumab (I) vs chemotherapy (C) in the phase III CheckMate 816 trial
- LBA50 Perioperative nivolumab (NIVO) v placebo (PBO) in patients (pts) with resectable NSCLC: Clinical update from the phase III CheckMate 77T study
- 1209MO Neoadjuvant nivolumab and nivolumab+ipilimumab in resectable non-small cell lung cancer: Combined analysis of 5-year outcomes from NEOSTAR and CA209-159
- 1210P Neoadjuvant pembrolizumab (pembro) or placebo (pbo) plus chemotherapy and adjuvant pembro or pbo for early stage NSCLC: Subgroup analyses of the phase III KEYNOTE-671 study
- OA02.03 Overall Survival (OS) with Neoadjuvant Nivolumab Plus Chemotherapy by Surgical Outcomes in the Phase 3 CheckMate 816 Study
- LBA9 Perioperative pembrolizumab in early-stage non–small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup
- Five-Year Outcomes of Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer From the Randomized KEYNOTE-671 Study
- EP05.02-019 Transitioning to Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: Surgical Outcomes in a Regionalized Pulmonary Oncology Network
- MA04.05 Patient-Reported Outcomes With Perioperative Nivolumab by Nodal Status in Patients With Resectable NSCLC From Checkmate 77T